Loading…

Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging

Peptide YY (PYY) and pancreatic polypeptide (PP) are two appetite suppressing hormones, released post-prandially from the ileum and pancreas, respectively. PYY(3-36) , the major circulating form of the peptide, is considered to reduce food intake in humans and rodents via high affinity binding to th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroendocrinology 2011-04, Vol.23 (4), p.371-380
Main Authors: Hankir, M K, Parkinson, J R C, Minnion, J S, Addison, M L, Bloom, S R, Bell, J D
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1103-56d761c6d7dd9b045c212e4b97195a678ae5002ed0c440b9bfa09e8ac5aff30d3
cites
container_end_page 380
container_issue 4
container_start_page 371
container_title Journal of neuroendocrinology
container_volume 23
creator Hankir, M K
Parkinson, J R C
Minnion, J S
Addison, M L
Bloom, S R
Bell, J D
description Peptide YY (PYY) and pancreatic polypeptide (PP) are two appetite suppressing hormones, released post-prandially from the ileum and pancreas, respectively. PYY(3-36) , the major circulating form of the peptide, is considered to reduce food intake in humans and rodents via high affinity binding to the auto-inhibitory neuropeptide Y receptor Y2R, whereas PP is considered to act through the Y4R. Current evidence indicates the anorexigenic effects of both peptides occur via signalling in the brainstem and arcuate nucleus (ARC) of the hypothalamus. Manganese-enhanced magnetic resonance imaging (MEMRI) has previously been used to track hypothalamic neuronal activity in vivo in response to both nutritional interventions and gut hormone treatment. In the present study, we used MEMRI to demonstrate that s.c. administration of PP results in a significant reduction in signal intensity (SI) in the ARC, ventromedial hypothalamus and paraventricular nucleus of fasted mice. Subcutaneous delivery of PYY(3-36) resulted in a nonsignificant trend towards decreased SI in the hypothalamus of fasted mice. We found no SI change in the area postrema of the brainstem after s.c. injection of either peptide. These differences in hypothalamic SI profile between PP and PYY(3-36) occurred despite both peptides producing a comparable reduction in food intake. These results suggest that separate central pathways control the anorexigenic response for PP and PYY(3-36) , possibly via a differential effect of Y4 receptor versus Y2 receptor signalling. In addition, we performed a series of MEMRI scans at 0-2, 2-4 and 4-6 h post-injection of PYY(3-36) and a potent analogue of the peptide; PYY(3-36) (LT). We recorded a significant reduction in the ARC SI 2-4 h after PYY(3-36) (LT) injection compared to both saline and PYY(3-36) in fasted mice. The physiological differences between PYY(3-36) and its analogue were also observed in the long-term effects on food intake, with PYY(3-36) (LT) producing a more sustained anorexigenic effect. These data suggest that MEMRI can be used to investigate the long-term effects of gut peptide delivery on activity within the hypothalamus and brainstem.
doi_str_mv 10.1111/j.1365-2826.2011.02111.x
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_858781899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>858781899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1103-56d761c6d7dd9b045c212e4b97195a678ae5002ed0c440b9bfa09e8ac5aff30d3</originalsourceid><addsrcrecordid>eNo9UE1PwzAMjZAQg8FfQLlxakmapR9HNPElIcEBDjtNbuJumdK0JO1E_xS_kUwMfLCl957tZxNCOUt5jNtdykUuk6zM8jRjnKcsi3D6dULO_4kZuQhhxxgvpGBnZJbxTHJWiXPy_Yb9YDTS1YqKROQUnKY9OOURBqNo39mpP0q0aRr06AYD1k7U42a0MCDdTn03bMFCGxscjr5zYCmowezNMFHjaCTwUPdm31EItEUIo0dN64m24DbgMGCCbhsXR7SFjcPDdo8hznKH5ogZt7kkpw3YgFfHOicfD_fvy6fk5fXxeXn3kijOmUhkroucq5i1rmq2kCpejIu6KnglIS9KQMlYhpqpxYLVVd0Aq7AEJaFpBNNiTm5-5_a--xwxDOvWBIXWRqfdGNalLIuSl1UVlddH5Vi3qNe9j1b9tP57sfgBXT6BzA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>858781899</pqid></control><display><type>article</type><title>Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging</title><source>Wiley</source><creator>Hankir, M K ; Parkinson, J R C ; Minnion, J S ; Addison, M L ; Bloom, S R ; Bell, J D</creator><creatorcontrib>Hankir, M K ; Parkinson, J R C ; Minnion, J S ; Addison, M L ; Bloom, S R ; Bell, J D</creatorcontrib><description>Peptide YY (PYY) and pancreatic polypeptide (PP) are two appetite suppressing hormones, released post-prandially from the ileum and pancreas, respectively. PYY(3-36) , the major circulating form of the peptide, is considered to reduce food intake in humans and rodents via high affinity binding to the auto-inhibitory neuropeptide Y receptor Y2R, whereas PP is considered to act through the Y4R. Current evidence indicates the anorexigenic effects of both peptides occur via signalling in the brainstem and arcuate nucleus (ARC) of the hypothalamus. Manganese-enhanced magnetic resonance imaging (MEMRI) has previously been used to track hypothalamic neuronal activity in vivo in response to both nutritional interventions and gut hormone treatment. In the present study, we used MEMRI to demonstrate that s.c. administration of PP results in a significant reduction in signal intensity (SI) in the ARC, ventromedial hypothalamus and paraventricular nucleus of fasted mice. Subcutaneous delivery of PYY(3-36) resulted in a nonsignificant trend towards decreased SI in the hypothalamus of fasted mice. We found no SI change in the area postrema of the brainstem after s.c. injection of either peptide. These differences in hypothalamic SI profile between PP and PYY(3-36) occurred despite both peptides producing a comparable reduction in food intake. These results suggest that separate central pathways control the anorexigenic response for PP and PYY(3-36) , possibly via a differential effect of Y4 receptor versus Y2 receptor signalling. In addition, we performed a series of MEMRI scans at 0-2, 2-4 and 4-6 h post-injection of PYY(3-36) and a potent analogue of the peptide; PYY(3-36) (LT). We recorded a significant reduction in the ARC SI 2-4 h after PYY(3-36) (LT) injection compared to both saline and PYY(3-36) in fasted mice. The physiological differences between PYY(3-36) and its analogue were also observed in the long-term effects on food intake, with PYY(3-36) (LT) producing a more sustained anorexigenic effect. These data suggest that MEMRI can be used to investigate the long-term effects of gut peptide delivery on activity within the hypothalamus and brainstem.</description><identifier>EISSN: 1365-2826</identifier><identifier>DOI: 10.1111/j.1365-2826.2011.02111.x</identifier><identifier>PMID: 21251093</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Brain Stem - drug effects ; Brain Stem - metabolism ; Eating - drug effects ; Fasting ; Humans ; Hypothalamus - cytology ; Hypothalamus - metabolism ; Magnetic Resonance Imaging - methods ; Male ; Manganese - metabolism ; Mice ; Mice, Inbred C57BL ; Neurons - cytology ; Neurons - drug effects ; Neurons - metabolism ; Pancreatic Polypeptide - metabolism ; Pancreatic Polypeptide - pharmacology ; Peptide Fragments ; Peptide YY - metabolism ; Peptide YY - pharmacology</subject><ispartof>Journal of neuroendocrinology, 2011-04, Vol.23 (4), p.371-380</ispartof><rights>2011 The Authors. Journal of Neuroendocrinology © 2011 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1103-56d761c6d7dd9b045c212e4b97195a678ae5002ed0c440b9bfa09e8ac5aff30d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21251093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hankir, M K</creatorcontrib><creatorcontrib>Parkinson, J R C</creatorcontrib><creatorcontrib>Minnion, J S</creatorcontrib><creatorcontrib>Addison, M L</creatorcontrib><creatorcontrib>Bloom, S R</creatorcontrib><creatorcontrib>Bell, J D</creatorcontrib><title>Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging</title><title>Journal of neuroendocrinology</title><addtitle>J Neuroendocrinol</addtitle><description>Peptide YY (PYY) and pancreatic polypeptide (PP) are two appetite suppressing hormones, released post-prandially from the ileum and pancreas, respectively. PYY(3-36) , the major circulating form of the peptide, is considered to reduce food intake in humans and rodents via high affinity binding to the auto-inhibitory neuropeptide Y receptor Y2R, whereas PP is considered to act through the Y4R. Current evidence indicates the anorexigenic effects of both peptides occur via signalling in the brainstem and arcuate nucleus (ARC) of the hypothalamus. Manganese-enhanced magnetic resonance imaging (MEMRI) has previously been used to track hypothalamic neuronal activity in vivo in response to both nutritional interventions and gut hormone treatment. In the present study, we used MEMRI to demonstrate that s.c. administration of PP results in a significant reduction in signal intensity (SI) in the ARC, ventromedial hypothalamus and paraventricular nucleus of fasted mice. Subcutaneous delivery of PYY(3-36) resulted in a nonsignificant trend towards decreased SI in the hypothalamus of fasted mice. We found no SI change in the area postrema of the brainstem after s.c. injection of either peptide. These differences in hypothalamic SI profile between PP and PYY(3-36) occurred despite both peptides producing a comparable reduction in food intake. These results suggest that separate central pathways control the anorexigenic response for PP and PYY(3-36) , possibly via a differential effect of Y4 receptor versus Y2 receptor signalling. In addition, we performed a series of MEMRI scans at 0-2, 2-4 and 4-6 h post-injection of PYY(3-36) and a potent analogue of the peptide; PYY(3-36) (LT). We recorded a significant reduction in the ARC SI 2-4 h after PYY(3-36) (LT) injection compared to both saline and PYY(3-36) in fasted mice. The physiological differences between PYY(3-36) and its analogue were also observed in the long-term effects on food intake, with PYY(3-36) (LT) producing a more sustained anorexigenic effect. These data suggest that MEMRI can be used to investigate the long-term effects of gut peptide delivery on activity within the hypothalamus and brainstem.</description><subject>Animals</subject><subject>Brain Stem - drug effects</subject><subject>Brain Stem - metabolism</subject><subject>Eating - drug effects</subject><subject>Fasting</subject><subject>Humans</subject><subject>Hypothalamus - cytology</subject><subject>Hypothalamus - metabolism</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>Manganese - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neurons - cytology</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Pancreatic Polypeptide - metabolism</subject><subject>Pancreatic Polypeptide - pharmacology</subject><subject>Peptide Fragments</subject><subject>Peptide YY - metabolism</subject><subject>Peptide YY - pharmacology</subject><issn>1365-2826</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNo9UE1PwzAMjZAQg8FfQLlxakmapR9HNPElIcEBDjtNbuJumdK0JO1E_xS_kUwMfLCl957tZxNCOUt5jNtdykUuk6zM8jRjnKcsi3D6dULO_4kZuQhhxxgvpGBnZJbxTHJWiXPy_Yb9YDTS1YqKROQUnKY9OOURBqNo39mpP0q0aRr06AYD1k7U42a0MCDdTn03bMFCGxscjr5zYCmowezNMFHjaCTwUPdm31EItEUIo0dN64m24DbgMGCCbhsXR7SFjcPDdo8hznKH5ogZt7kkpw3YgFfHOicfD_fvy6fk5fXxeXn3kijOmUhkroucq5i1rmq2kCpejIu6KnglIS9KQMlYhpqpxYLVVd0Aq7AEJaFpBNNiTm5-5_a--xwxDOvWBIXWRqfdGNalLIuSl1UVlddH5Vi3qNe9j1b9tP57sfgBXT6BzA</recordid><startdate>201104</startdate><enddate>201104</enddate><creator>Hankir, M K</creator><creator>Parkinson, J R C</creator><creator>Minnion, J S</creator><creator>Addison, M L</creator><creator>Bloom, S R</creator><creator>Bell, J D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201104</creationdate><title>Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging</title><author>Hankir, M K ; Parkinson, J R C ; Minnion, J S ; Addison, M L ; Bloom, S R ; Bell, J D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1103-56d761c6d7dd9b045c212e4b97195a678ae5002ed0c440b9bfa09e8ac5aff30d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Brain Stem - drug effects</topic><topic>Brain Stem - metabolism</topic><topic>Eating - drug effects</topic><topic>Fasting</topic><topic>Humans</topic><topic>Hypothalamus - cytology</topic><topic>Hypothalamus - metabolism</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>Manganese - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neurons - cytology</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Pancreatic Polypeptide - metabolism</topic><topic>Pancreatic Polypeptide - pharmacology</topic><topic>Peptide Fragments</topic><topic>Peptide YY - metabolism</topic><topic>Peptide YY - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hankir, M K</creatorcontrib><creatorcontrib>Parkinson, J R C</creatorcontrib><creatorcontrib>Minnion, J S</creatorcontrib><creatorcontrib>Addison, M L</creatorcontrib><creatorcontrib>Bloom, S R</creatorcontrib><creatorcontrib>Bell, J D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroendocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hankir, M K</au><au>Parkinson, J R C</au><au>Minnion, J S</au><au>Addison, M L</au><au>Bloom, S R</au><au>Bell, J D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging</atitle><jtitle>Journal of neuroendocrinology</jtitle><addtitle>J Neuroendocrinol</addtitle><date>2011-04</date><risdate>2011</risdate><volume>23</volume><issue>4</issue><spage>371</spage><epage>380</epage><pages>371-380</pages><eissn>1365-2826</eissn><abstract>Peptide YY (PYY) and pancreatic polypeptide (PP) are two appetite suppressing hormones, released post-prandially from the ileum and pancreas, respectively. PYY(3-36) , the major circulating form of the peptide, is considered to reduce food intake in humans and rodents via high affinity binding to the auto-inhibitory neuropeptide Y receptor Y2R, whereas PP is considered to act through the Y4R. Current evidence indicates the anorexigenic effects of both peptides occur via signalling in the brainstem and arcuate nucleus (ARC) of the hypothalamus. Manganese-enhanced magnetic resonance imaging (MEMRI) has previously been used to track hypothalamic neuronal activity in vivo in response to both nutritional interventions and gut hormone treatment. In the present study, we used MEMRI to demonstrate that s.c. administration of PP results in a significant reduction in signal intensity (SI) in the ARC, ventromedial hypothalamus and paraventricular nucleus of fasted mice. Subcutaneous delivery of PYY(3-36) resulted in a nonsignificant trend towards decreased SI in the hypothalamus of fasted mice. We found no SI change in the area postrema of the brainstem after s.c. injection of either peptide. These differences in hypothalamic SI profile between PP and PYY(3-36) occurred despite both peptides producing a comparable reduction in food intake. These results suggest that separate central pathways control the anorexigenic response for PP and PYY(3-36) , possibly via a differential effect of Y4 receptor versus Y2 receptor signalling. In addition, we performed a series of MEMRI scans at 0-2, 2-4 and 4-6 h post-injection of PYY(3-36) and a potent analogue of the peptide; PYY(3-36) (LT). We recorded a significant reduction in the ARC SI 2-4 h after PYY(3-36) (LT) injection compared to both saline and PYY(3-36) in fasted mice. The physiological differences between PYY(3-36) and its analogue were also observed in the long-term effects on food intake, with PYY(3-36) (LT) producing a more sustained anorexigenic effect. These data suggest that MEMRI can be used to investigate the long-term effects of gut peptide delivery on activity within the hypothalamus and brainstem.</abstract><cop>United States</cop><pmid>21251093</pmid><doi>10.1111/j.1365-2826.2011.02111.x</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1365-2826
ispartof Journal of neuroendocrinology, 2011-04, Vol.23 (4), p.371-380
issn 1365-2826
language eng
recordid cdi_proquest_miscellaneous_858781899
source Wiley
subjects Animals
Brain Stem - drug effects
Brain Stem - metabolism
Eating - drug effects
Fasting
Humans
Hypothalamus - cytology
Hypothalamus - metabolism
Magnetic Resonance Imaging - methods
Male
Manganese - metabolism
Mice
Mice, Inbred C57BL
Neurons - cytology
Neurons - drug effects
Neurons - metabolism
Pancreatic Polypeptide - metabolism
Pancreatic Polypeptide - pharmacology
Peptide Fragments
Peptide YY - metabolism
Peptide YY - pharmacology
title Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T15%3A16%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peptide%20YY%203-36%20and%20pancreatic%20polypeptide%20differentially%20regulate%20hypothalamic%20neuronal%20activity%20in%20mice%20in%20vivo%20as%20measured%20by%20manganese-enhanced%20magnetic%20resonance%20imaging&rft.jtitle=Journal%20of%20neuroendocrinology&rft.au=Hankir,%20M%20K&rft.date=2011-04&rft.volume=23&rft.issue=4&rft.spage=371&rft.epage=380&rft.pages=371-380&rft.eissn=1365-2826&rft_id=info:doi/10.1111/j.1365-2826.2011.02111.x&rft_dat=%3Cproquest_pubme%3E858781899%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1103-56d761c6d7dd9b045c212e4b97195a678ae5002ed0c440b9bfa09e8ac5aff30d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=858781899&rft_id=info:pmid/21251093&rfr_iscdi=true